Mobile Wearable Health Device in Bio-monitoring Patients with Newly Diagnosed Multiple Myeloma Receiving Induction Chemotherapy

Inclusion Criteria

• Newly diagnosed multiple myeloma meeting International Myeloma Working Group (IMWG) criteria (as below) patients with clinical and histological confirmation of diagnosis planning to receive chemotherapy are eligible: * Newly diagnosed multiple myeloma patients will have evidence of underlying end organ damage and/or myeloma defining event attributed to underlying plasma cell proliferative disorder meeting at least one of the following: * Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) above upper limit of normal or >= 2.75 mmol/L (11 mg/dL) * Anemia: hemoglobin value < 10 g/dL or > 2 g/dL below lower limit of normal * Bone disease: >= 1 lytic lesions on skeletal X-ray, computed tomography (CT), or positron emission tomography (PET)-computed tomography (CT); for patients with 1 lytic lesion, bone marrow should demonstrate >= 10% clonal plasma cells * Clonal bone marrow plasma cell percentage >= 60% * Involved/un-involved serum free light chain ratio >= 100 and involved free light chain > 100 mg/L * > 1 focal lesion on magnetic resonance imaging study (lesion must be > 5 mm) in size
• All study patients will be required to receive primary chemotherapy treatment at -a Memorial Sloan Kettering facility, including regional outpatient sites
• All study patients will be required to have a smart phone or tablet device compatible with the Garmin Vivofit device

Exclusion Criteria

• Plasma cell leukemia
• Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome
• Amyloidosis